Can One App Help Stem the Tide of Opioid Abuse?

2018-12-13 14:58:39 Omed

Digital health solutions could be the most viable means of curbing the opioid abuse epidemic. FDA contributed to the support of this belief earlier this week, when it gave a nod to Pear Therapeutics’ mobile medical app. The solution, called reSET-O, is used to help those with opioid use disorder stay in recovery programs.

The Boston, MA-based company said the reSET-O app is a prescription cognitive behavioral therapy intended to be used in addition to outpatient treatment under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management.

“As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” Scott Gittlieb, MD, FDA commissioner said in a release. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Nearly 170 patients were evaluated in a 12-week clinical trial of a desktop version of reSET-O. Data from the trial showed a statistically significant increase in retention in a treatment program for 12 weeks for the patients who used the desktop computer version of the reSET-O program compared to those who did not. In the trial, patients who used the desktop computer version of reSET-O had an overall retention rate through the end of 12 weeks of treatment of 82.4% compared with 68.45% overall retention rate for patients who did not.

FDA used the data to make a clearance determination for reSET-O.

This isn’t Pear Therapeutics’ first rodeo with FDA. In September of last year the company received a nod to market reSET, a solution that it said was the first app given approval to treat substance abuse. The app was cleared for use as an adjuvant to standard outpatient therapy to treat patients with substance use disorder for stimulants, cannabis, cocaine, and alcohol.

 

閱讀全文
  • 相關廠商

    醫百科技股份有限公司

    醫百科技股份有限公司為一專業高科技醫療器材公司。身為導航系統之技術領先者,醫百不斷追求技術之創新與彈性化之產品組合來因應醫療臨床與教育市場上各種挑戰。本公司產品特色「科技、精準、微創、安全」,且本公司之產品在於強調"即時",由於光學導引技術皆由醫百科技開發而出,因此皆可掌握住關鍵技術不斷做修正,不論是教育產品或是結合電腦斷層與核磁共振技術與光學定位系統導引的臨床產品,能使醫師對病患做三維影像的分析與診斷後,利用即時系統來節省醫師手術時間,提高手術成功率與安全性。 醫百科技最新產品「雷帝納手術導航系統」是用於顱部之手術定位導引的系統,可於術中進行即時導航,即時呈現器械位置。醫生可有個更安全且更精準的微創手術。該系統結合智慧醫療概念,統整數位醫療影像,增加手術精準度,減少不必要的組織傷害,達到微創手術效果,改善手術品質,降低手術合併症風險,從而為患者提供更好的醫療服務。另外,「雷帝納」系統有著與其他儀器設備高度兼容性,可以為技術援助提供準確,安全的結果,大大降低手術風險。 獲獎經歷: - 2008年生技醫療星光大道 先鋒獎 - 2009年破殼而出中小企業創新育成中心培育優質企業獎 - 2015年臺灣精品獎 - 2016年Iris、CDS同時榮獲資訊月百大創新金質獎 - 2016年榮獲衛福部‧經濟部藥物科技研究發展獎銅質獎 醫百科技也已分別取得ISO13485以及醫療器材GMP品質管理認證,並已取得歐盟CE認證、台灣TFDA第二類醫材認證,以及中國大陸植牙導航系統CFDA第三類醫材認證。


    京達醫材科技股份有限公司

    在行政院經濟部「科專獎勵推動人工植牙(植體)產業」的計畫下,京達醫材於2008年正式成立,應用國家雷射技術,專注於人工牙根設計與製造,獲政府資源大力挹注與支持,投資數億元。目前兩大GMP廠房座落於高雄科學園區,擁有高尖端醫療生產設備,所有的產品皆為自有工廠所生產,並結合台灣專業醫學大學研究單位及植體相關公協會醫師群,組成跨領域研發團隊,從醫師的需求立場,共同開發出BIOMATE人工牙根植體系統,堅持品質,台灣研發、製造與生產,開發出最符合病人骨型的人工牙根植體系統,並成立數位牙體技工中心及數位植牙教育訓練中心,提供全方位牙科解決方案。


    喜樂醫療器材股份有限公司

    喜樂醫材(JMD)是一高度研發導向並致力於提升醫療器材品質之醫療器材公司。JMD於2009年設廠進駐於台灣南部科學園區,開發並生產一系列創新的骨科與牙科用的醫療器材產品,包含一般型及非使用抗生素的抗菌型高誘骨、高骨置換率之Ezechbone®系列的鈣基骨泥及骨粒產品,並搭配其使用之微創手術用高孔隙骨粒及骨泥傳輸系統(jBranch™)。其它創新技術如微創擴骨系統、高強度/低彈性模數之牙科鑄造及植入型Ti-Mo合金、可臨床調整形狀的顱顏面迷你骨板、新一代人工牙根等,也將陸續問世。